Assenagon Asset Management
TVTX icon

Assenagon Asset Management’s Travere Therapeutics TVTX Stock Holding History

Assenagon Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3M Buy
427,305
+419,378
+5,291% +$18.6M 0.03% 365
2026
Q1 		$236K Sell
7,927
-409,815
-98% -$12.3M ﹤0.01% 1069
2025
Q4 		$16M Buy
417,742
+324,387
+347% +$10.5M 0.02% 406
2025
Q3 		$2.23M Sell
93,355
-1,009,720
-92% -$19M ﹤0.01% 805
2025
Q2 		$16.3M Buy
1,103,075
+689,561
+167% +$11.4M 0.02% 382
2025
Q1 		$7.41M Sell
413,514
-116,999
-22% -$2.37M 0.01% 474
2024
Q4 		$9.24M Sell
530,513
-844,009
-61% -$14.9M 0.01% 535
2024
Q3 		$19.2M Sell
1,374,522
-839,577
-38% -$8.75M 0.04% 353
2024
Q2 		$18.2M Buy
2,214,099
+1,995,419
+912% +$13.4M 0.04% 308
2024
Q1 		$1.69M Sell
218,680
-35,371
-14% -$298K ﹤0.01% 944
2023
Q4 		$2.28M Hold
254,051
– – 0.01% 872
2023
Q3 		$2.27M Sell
254,051
-843,994
-77% -$11.9M 0.01% 813
2023
Q2 		$16.9M Sell
1,098,045
-560,644
-34% -$10.2M 0.06% 258
2023
Q1 		$37.3M Buy
1,658,689
+791,270
+91% +$16.8M 0.13% 137
2022
Q4 		$18.2M Sell
867,419
-57,095
-6% -$1.21M 0.07% 260
2022
Q3 		$22.8M Sell
924,514
-25,951
-3% -$670K 0.09% 225
2022
Q2 		$23M Buy
950,465
+639,114
+205% +$16.1M 0.09% 208
2022
Q1 		$8.02M Buy
311,351
+115,820
+59% +$3.08M 0.02% 422
2021
Q4 		$6.07M Buy
+195,531
New +$5.51M 0.02% 461
2020
Q4 		– Sell
-359,761
Closed -$6.64M – 1268
2020
Q3 		$6.64M Buy
359,761
+195,592
+119% +$3.8M 0.04% 268
2020
Q2 		$3.35M Sell
164,169
-266,277
-62% -$4.24M 0.02% 435
2020
Q1 		$6.28M Buy
+430,446
New +$6.48M 0.05% 200
2019
Q1 		– Sell
-21,808
Closed -$494K – 1120
2018
Q4 		$494K Buy
+21,808
New +$542K 0.01% 823

Other funds holding TVTX

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
HCMT
Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Assenagon Asset Management's TVTX Position: Q2 2026 in Review

Assenagon Asset Management increased its Travere Therapeutics (TVTX) stake by 5,291% in Q2 2026, buying an estimated $18.6M and bringing the position to 427,305 shares worth $24.3M. The position accounts for 0.03% of the portfolio, ranked #365.

Assenagon Asset Management first reported a position in TVTX in Q4 2018 and has held it in 23 quarters since. The position peaked at $37.3M in Q1 2023. 32 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Assenagon Asset Management held 427,305 shares of Travere Therapeutics worth $24.3M as of Q2 2026.
  • Assenagon Asset Management bought 419,378 Travere Therapeutics shares in Q2 2026, an estimated $18.6M.
  • Travere Therapeutics made up 0.03% of Assenagon Asset Management's portfolio in Q2 2026, its #365 holding.
  • Assenagon Asset Management first reported a position in Travere Therapeutics in Q4 2018 and has held it in 23 quarters since.
  • Assenagon Asset Management's Travere Therapeutics position peaked at $37.3M in Q1 2023.
  • 32 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.